IMU

4.00%

4.8¢ imugene limited

Any potential partner would have full access to IMU’s data room....

First 80 Last

Share
Profile

Follow
Taureanbull

3,313 Posts.

7334

21/02/19

08:46

Post #: 37509989
Share

Originally posted by Mer ↑

Originally posted by supertramp
Fair enough W...

But one never knows how close a partnership could be. imu have a very safe and disruptive technology in a very valuable and growing area.

The company's silence might indicate that negotiations are deep - or that nothing is happening.

I value imu's enterprise value as many times the current, so I'm happy to hold. But I also understand people moving on.

cheers
Super

. . .
one never knows how close a partnership could be
. . . True, although that does play into FOMO.

. . .
The company's silence might indicate that negotiations are deep - or that nothing is happening. . . IMU used to constantly stress how many early deals were getting done and how keen they are to do something similar. They aren't banging that drum much these days; maybe it's because they don't need to raise money(cynical), maybe it's not seen as an option any more. However, having just done a bit of promotion in San Francisco, perhaps a few talks are underway. A bit of drum banging here, but the San Francisco poster was the first mention(as far as I can tell) of a LT dosing schedule - 6 weeks after day 56 and every 12 weeks thereafter. Whatever they've found out in the 1b, it led them to add extra patients to the 3rd cohort and tack some LT dosing on the end; I doubt that either would have happened if it wasn't seen as beneficial to the patients. Possibly some interesting results we haven't seen yet, but whether or not a potential partner could see them under cover of a non-disclosure agreement I don't know. Lots of conjecture, bit of a house of cards.

They were cracking on with the P2 arrangements last year and if they've talked with the FDA, I'll be surprised if there's a long wait for some info about P2. Likewise key-vaxx, which was obviously a high and speedy priority.

Cheers

Expand

Any potential partner would have full access to IMU’s data room. Everything the CEO knows is in that data room. The CEO would not be out discussing deals if confidential talks were underway.

IMU Price at posting: 1.7¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

The winners & losers on market if negative gearing were gone

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The market's shrugged at China's stimulus measures all year. Why is this one different?

There are more pages in this discussion • 61 more messages in this thread...

First 80 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change -0.002(4.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
5.0¢	5.0¢	4.7¢	$2.298M	47.86M

Buyers (Bids)

No.	Vol.	Price($)
5	1925982	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	3452098	12

View Market Depth

No.	Vol.	Price($)
5	1925982	0.048
44	6409183	0.047
52	5062868	0.046
58	6807888	0.045
13	2613180	0.044

Price($)	Vol.	No.
0.049	3452098	12
0.050	3513781	16
0.051	7159676	14
0.052	2071350	7
0.053	818882	6

Last trade - 16.10pm 27/09/2024 (20 minute delay)

IMU (ASX) Chart

Any potential partner would have full access to IMU’s data room....

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Zeta Resources seeks to resolve the Panoramic takeover story

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Any potential partner would have full access to IMU’s data room....

Top Stories

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Zeta Resources seeks to resolve the Panoramic takeover story

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News